Alnylam Pharmaceuticals (ALNY) 'Appears Oversold' on BridgeBio Pharma News - Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
Go back to Alnylam Pharmaceuticals (ALNY) 'Appears Oversold' on BridgeBio Pharma News - Oppenheimer
December 28, 2021 6:02 AM EST
Oppenheimer analyst Leland Gershell reiterates an "Outperform" rating and $200 price target on the shares of Alnylam Pharma (NASDAQ: ALNY), following disappointing Phase 3 data of the company's competitor - BridgeBio Pharma, Inc. (Nasdaq: BBIO). The analyst believes the... More
December 27, 2021 9:21 AM EST
Shares of BridgeBio Pharma (Nasdaq: BBIO) are down nearly 70% today after the company announced topline results from Month 12 (Part A) of ATTRibute-CM.
The ongoing global Phase 3 study is investigating acoramidis for the treatment of symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).
BIO said that observes declines 6MWD at Month 12 in participants receiving acoramidis or placebo were substantially less than the >40 meter annual declines observed in... More
December 27, 2021 7:52 AM EST
Stifel analyst Paul Matteis said BridgeBio Pharma's (NASDAQ: BBIO) failure today of its... More
